Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded at Zacks Research

Zacks Research upgraded shares of Sensei Biotherapeutics (NASDAQ:SNSE) to a hold rating in a report published on Tuesday,Zacks.com reports.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded Sensei Biotherapeutics to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. Finally, Leerink Partners began coverage on Sensei Biotherapeutics in a research report on Monday. They set an “outperform” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $40.00.

Sensei Biotherapeutics Trading Up 3.1%

NASDAQ:SNSE opened at $32.62 on Tuesday. Sensei Biotherapeutics has a twelve month low of $5.25 and a twelve month high of $36.76. The company has a market cap of $43.71 million, a price-to-earnings ratio of -1.96 and a beta of -0.10. The stock has a fifty day simple moving average of $29.25 and a 200-day simple moving average of $16.55.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its earnings results on Monday, March 30th. The company reported ($3.74) earnings per share for the quarter, topping the consensus estimate of ($4.81) by $1.07. As a group, equities research analysts predict that Sensei Biotherapeutics will post -2.77 EPS for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.